[Click eStock] "Qurient, Ongoing Expectations for Technology Export"

Daishin Securities stated on the 23rd that expectations remain high for the technology export of Qurient's 'QP101' and 'Q901'. The company did not provide an investment opinion or target price.

Qurient is a company that was spun off from the Institut Pasteur Korea and began developing tuberculosis treatments. It is currently developing new drugs by introducing oncology pipeline technologies from the Max Planck Institute, one of Europe's largest basic science research institutes.

Kim Ahyoung, a researcher at Daishin Securities, explained, "Q901 selectively inhibits CDK7, thereby inducing both cell cycle regulation and transcriptional suppression. This suppresses the expression of DNA damage repair genes and is drawing attention as a core strategy for overcoming ADC resistance in combination therapies." She emphasized, "Currently, Q901 is in the final stage of high-dose administration in its phase 1 monotherapy trial, and based on the results from this high-dose administration, Qurient plans to begin full-scale technology export discussions with major global pharmaceutical companies."

She added, "QP101 is a dual payload ADC that simultaneously incorporates Topo1i and CDK7i. Among various combination candidates, it is evaluated as having the most potent mechanism of action. If a platform deal is achieved at the preclinical stage, the company could be revalued as a platform company."

Kim further stated, "QP101 is currently at the preclinical stage, while Q901 is about to administer the final high-dose to the last patient in its phase 1 clinical trial. If Q901 delivers meaningful results in phase 1, the likelihood of technology export to major global pharmaceutical companies is expected to increase."